Chronic graft-versus-host disease: Where do we go from here?

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.

Original languageEnglish (US)
Pages (from-to)569-577
Number of pages9
JournalBone Marrow Transplantation
Volume33
Issue number6
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Graft vs Host Disease
Therapeutics
Stem Cell Transplantation
Treatment Failure
Cyclosporine
Adrenal Cortex Hormones
Retrospective Studies
Clinical Trials
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • Allogeneic stem cell transplantation
  • Chronic graft-versus-host disease
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Chronic graft-versus-host disease : Where do we go from here? / Farag, Sherif.

In: Bone Marrow Transplantation, Vol. 33, No. 6, 03.2004, p. 569-577.

Research output: Contribution to journalArticle

@article{b59e21c35fb54465a47f45cb9b630579,
title = "Chronic graft-versus-host disease: Where do we go from here?",
abstract = "Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.",
keywords = "Allogeneic stem cell transplantation, Chronic graft-versus-host disease, Prognosis",
author = "Sherif Farag",
year = "2004",
month = "3",
doi = "10.1038/sj.bmt.1704410",
language = "English (US)",
volume = "33",
pages = "569--577",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Chronic graft-versus-host disease

T2 - Where do we go from here?

AU - Farag, Sherif

PY - 2004/3

Y1 - 2004/3

N2 - Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.

AB - Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.

KW - Allogeneic stem cell transplantation

KW - Chronic graft-versus-host disease

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=1842483199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842483199&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704410

DO - 10.1038/sj.bmt.1704410

M3 - Article

C2 - 14743199

AN - SCOPUS:1842483199

VL - 33

SP - 569

EP - 577

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -